US FDA okays Merck's new once-daily HIV pill

The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir

Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal to advance cancer treatment

Experts discuss ways to strengthen adolescent mental health through ANUMATI 2.0

Policy symposium in Hyderabad focuses on life skills education and community?driven solutions

Roche’s MS drug fenebrutinib delivers striking Phase III results by cutting relapse rates by 58%

The company announced that its Phase III FENhance 1 and 2 studies both met their primary endpoints

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche

The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents

Ultomiris shows strong interim results in Phase III IgA nephropathy trial

IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys

Samsung Bioepis unveils promising preclinical data for novel ADC SBE303 at AACR 2026

SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers

K J Somaiya Hospital develops 10-minute tests to bridge India’s haemophilia diagnosis gap

These tests deliver results in 10–15 minutes at a cost of Rs 100–Rs 150, compared to conventional diagnostics which cost up to Rs 15,000

Aurobindo Pharma bags USFDA nod for Glycerol Phenylbutyrate Oral Liquid

The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics

MicrobioTx launches IBS Risk Score to enable early detection of gut disorder

The launch coincides with IBS Awareness Month in April